Immunotherapy combo shows promise in early ovarian cancer trial
NCT ID NCT03245892
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested whether adding the immunotherapy drugs nivolumab (with or without ipilimumab) to standard chemotherapy could be safe for people with advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. 27 participants received the drug combinations before and after surgery. The main goal was to check for serious side effects, not yet to measure how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab and ipilimumab (immunotherapy drugs) plus carboplatin and paclitaxel (chemotherapy)
- What this could lead to
- If successful, this could point toward a more effective treatment approach for advanced ovarian cancer by combining immunotherapy with standard chemotherapy.
- What could go wrong
- This is a very early Phase 1 safety study with only 27 participants, so it cannot prove the treatment works. There is a risk of serious side effects from the drug combinations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?
- New drug cocktail aims to shrink recurrent ovarian tumors
- New drug combo aims to stall ovarian cancer in patients without common DNA repair flaw
- Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?